# Avapritinib in CBF-AML With KIT Mutations

> **NCT05821738** · PHASE2 · UNKNOWN · sponsor: **The First Affiliated Hospital of Soochow University** · enrollment: 50 (estimated)

## Conditions studied

- Core Binding Factor Acute Myeloid Leukemia
- KIT Mutation-Related Tumors

## Interventions

- **DRUG:** Avapritinib

## Key facts

- **NCT ID:** NCT05821738
- **Lead sponsor:** The First Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-01
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2023-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05821738

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05821738, "Avapritinib in CBF-AML With KIT Mutations". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05821738. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*